Simon P. Joel

1.9k total citations · 1 hit paper
36 papers, 1.5k citations indexed

About

Simon P. Joel is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Simon P. Joel has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Hematology. Recurrent topics in Simon P. Joel's work include Multiple Myeloma Research and Treatments (5 papers), Cancer therapeutics and mechanisms (5 papers) and Pain Mechanisms and Treatments (5 papers). Simon P. Joel is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Cancer therapeutics and mechanisms (5 papers) and Pain Mechanisms and Treatments (5 papers). Simon P. Joel collaborates with scholars based in United Kingdom, United States and Japan. Simon P. Joel's co-authors include Robert te Poele, Andrei L. Okorokov, Lesley Jardine, Jeffrey L. Cummings, M L Slevin, Lenushka Maharaj, Simone Jüliger, Tim Lister, Sandra J. Strauss and David P. Schenkein and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Simon P. Joel

36 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

2002 537 citations Robert te Poele, Andrei L. Okorokov et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon P. Joel United Kingdom	18	828	483	383	190	134	36	1.5k
Evan E. Opas United States	18	820 1.0×	594 1.2×	359 0.9×	74 0.4×	272 2.0×	34	2.0k
Halina Waś Poland	19	1.6k 1.9×	261 0.5×	199 0.5×	212 1.1×	171 1.3×	34	2.2k
Jaya P. Gnana‐Prakasam United States	22	1.2k 1.5×	268 0.6×	323 0.8×	55 0.3×	141 1.1×	39	2.1k
Arun Kumar Trivedi India	24	940 1.1×	327 0.7×	159 0.4×	58 0.3×	162 1.2×	70	1.5k
Xu Di United States	19	790 1.0×	336 0.7×	315 0.8×	115 0.6×	179 1.3×	25	1.4k
Françoise Bontemps Belgium	24	1.1k 1.4×	213 0.4×	266 0.7×	171 0.9×	85 0.6×	71	2.0k
Xavier Deschênes‐Simard Canada	11	1.0k 1.3×	368 0.8×	655 1.7×	82 0.4×	300 2.2×	18	1.8k
Merlijn Bazuine Netherlands	17	1.0k 1.3×	630 1.3×	375 1.0×	70 0.4×	166 1.2×	18	1.8k
Hiroshi Kuwata Japan	20	1.1k 1.4×	177 0.4×	250 0.7×	79 0.4×	208 1.6×	43	1.9k
Michaela Artwohl Austria	18	448 0.5×	184 0.4×	220 0.6×	55 0.3×	163 1.2×	23	1.0k

Countries citing papers authored by Simon P. Joel

Since Specialization

Citations

This map shows the geographic impact of Simon P. Joel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon P. Joel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon P. Joel more than expected).

Fields of papers citing papers by Simon P. Joel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon P. Joel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon P. Joel. The network helps show where Simon P. Joel may publish in the future.

Co-authorship network of co-authors of Simon P. Joel

This figure shows the co-authorship network connecting the top 25 collaborators of Simon P. Joel. A scholar is included among the top collaborators of Simon P. Joel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon P. Joel. Simon P. Joel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghazaly, Essam, Farideh Miraki‐Moud, Robert Petty, et al.. (2020). Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. Journal of Biological Chemistry. 295(16). 5496–5508. 7 indexed citations

Kassam, Shireen, Heidi Goenaga‐Infante, Lenushka Maharaj, et al.. (2011). Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines. Cancer Chemotherapy and Pharmacology. 68(3). 815–821. 29 indexed citations

Noël, Elodie, Marc Yeste‐Velasco, Xueying Mao, et al.. (2010). The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. American Journal Of Pathology. 176(6). 2607–2615. 86 indexed citations

Goenaga‐Infante, Heidi, et al.. (2010). Capabilities of HPLC with APEX-Q nebulisation ICP-MS and ESI MS/MS to compare selenium uptake and speciation of non-malignant with different B cell lymphoma lines. Analytical and Bioanalytical Chemistry. 399(5). 1789–1797. 4 indexed citations

Noël, Elodie, Tracy Chaplin, Xueying Mao, et al.. (2008). Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines. Genes Chromosomes and Cancer. 47(7). 604–613. 16 indexed citations

Jüliger, Simone, Takayuki Nakashima, Lenushka Maharaj, et al.. (2008). A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.. Blood. 112(11). 1625–1625. 3 indexed citations

Jüliger, Simone, Heidi Goenaga‐Infante, Tim Lister, Jude Fitzgibbon, & Simon P. Joel. (2007). Chemosensitization of B-Cell Lymphomas by Methylseleninic Acid Involves Nuclear Factor-κB Inhibition and the Rapid Generation of Other Selenium Species. Cancer Research. 67(22). 10984–10992. 32 indexed citations

Marson, Charles M., Stéphane Sengmany, John P. Alao, et al.. (2006). Structure–activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 17(1). 136–141. 16 indexed citations

Penson, Richard T., et al.. (2005). Morphine analgesia in cancer pain: Role of the glucuronides. Journal of Opioid Management. 1(2). 83–90. 14 indexed citations

10.

Liu, Wai M., Sandra J. Strauss, Tracy Chaplin, et al.. (2004). s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. The Hematology Journal. 5(3). 247–254. 19 indexed citations

11.

Ribeiro, Maria DC, Simon P. Joel, & Giovambattista Zeppetella. (2004). The bioavailability of morphine applied topically to cutaneous ulcers. Journal of Pain and Symptom Management. 27(5). 434–439. 43 indexed citations

12.

Stachulski, Andrew V., Feodor Scheinmann, Peter Hopkins, et al.. (2003). Structure–activity relationships of some opiate glycosides. Bioorganic & Medicinal Chemistry Letters. 13(6). 1207–1214. 13 indexed citations

13.

Liu, Wai M. & Simon P. Joel. (2003). The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemotherapy and Pharmacology. 51(4). 291–296. 16 indexed citations

14.

Penson, Richard T., et al.. (2002). The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine‐6‐glucuronide. British Journal of Clinical Pharmacology. 53(4). 347–354. 40 indexed citations

15.

Penson, Richard T., et al.. (2001). Limited Phase I Study of Morphine-3-Glucuronide. Journal of Pharmaceutical Sciences. 90(11). 1810–1816. 51 indexed citations

16.

Poele, Robert te, Andrei L. Okorokov, & Simon P. Joel. (1999). RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene. 18(42). 5765–5772. 50 indexed citations

17.

Liu, Wai M., et al.. (1998). Effects of haemopoietic growth factors in combination with etoposide on sister chromatid exchange frequencies in peripheral blood mononuclear cells. Cancer Chemotherapy and Pharmacology. 41(4). 343–346. 3 indexed citations

18.

Joel, Simon P. & M L Slevin. (1994). Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemotherapy and Pharmacology. 34(S1). S84–S88. 17 indexed citations

19.

Joel, Simon P., Richard J. Osborne, & M L Slevin. (1994). Reply. Clinical Pharmacology & Therapeutics. 56(1). 114–114. 1 indexed citations

20.

Slevin, M L, et al.. (1989). The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemotherapy and Pharmacology. 24(5). 329–331. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact